Showing 2441-2450 of 5644 results for "".
- Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22https://modernod.com/news/prevent-blindness-declares-second-annual-inherited-retinal-disease-ird-genetic-testing-week-as-may-16-22/2479209/Prevent Blindness has declared the second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” as May 16-22, 2021. As part of this initiative, Prevent Blindness will be posting a series of educational graphics on its social media channels, including Facebook, Twitter, and Instagram.
- NUST MISIS Scientists Say They Developed a Safe Drug to Treat Eye Inflammationhttps://modernod.com/news/nust-misis-scientists-say-they-developed-a-safe-drug-to-treat-eye-inflammation/2479203/A Russian-American research team from The National University of Science and Technology MISIS has presented a new therapeutic method using nanoparticles of an antioxidant enzyme, developed specifically for the eyes. It relieves inflammation and repairs tissue without causing side effects: irritat
- Lumenis Named “Best Overall Medical Device Company” in 2021 MedTech Breakthrough Awardshttps://modernod.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/Lumenis announced that it has been selected as the “Best Overall Medical Device Company” in the MedTech Breakthrough Awards. MedTech Breakthrough is an independent market intelligence organization that honors excellence and recognizes the top companies, technologies and products in the global he
- PharmAbcine Announces Nonclinical Data of PMC-403 for Vessel-Related Diseases at ARVOhttps://modernod.com/news/pharmabcine-announces-nonclinical-data-of-pmc-403-for-vessel-related-diseases-at-arvo/2479187/PharmAbcine announced that the company presented an e-poster featuring nonclinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5th. PMC-403 is the company’s novel agonistic ant
- Verana Health: Study Demonstrates Promise of Real-World Data in Ophthalmic Clinical Developmenthttps://modernod.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/Verana Health unveiled research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercepthttps://modernod.com/news/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/2479150/Novartis announced positive 1-year results of the phase III KESTREL and KITE studies, evaluating the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of noninferiority in change in best corrected visual acuity (
- Nova Eye Medical Announces First Patient Enrolled in MAGIC Multicenter Canaloplasty Trial for Glaucomahttps://modernod.com/news/nova-eye-medical-announces-first-patient-enrolled-in-magic-multicenter-canaloplasty-trial-for-glaucoma/2479145/Nova Eye Medical Limited announced the enrollment of the first glaucoma patient in the multicenter ab-interno glaucoma study investigating canaloplasty (MAGIC) trial. The first MAGIC patie
- Ophthalmic World Leaders Announces Development and Networking Program for Executives Seeking Corporate Board Positionshttps://modernod.com/news/ophthalmic-world-leaders-announces-development-and-networking-program-for-executives-seeking-corporate-board-positions/2479130/Ophthalmic World Leaders (OWL) has announced its inaugural “Get-On-Board with OWL” program. Primarily aimed at executive-level women and underrepresented communities, this new offering will help attendees develop the skills and connections required to secure board positions in a rapid
- Eyemate System for Remote Glaucoma Management Obtains FDA Breakthrough Device Designationhttps://modernod.com/news/eyemate-system-for-remote-glaucoma-management-obtains-fda-breakthrough-device-designation/2479126/Implandata Ophthalmic Products announced today that its Eyemate system for digitally enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the US FDA. A BDD is only assigned for breakthrough technologies that have the potential to pro